Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Acute Lymphoblastic Leukemia
52%
Reduced-intensity Conditioning
47%
Overall Survival
40%
Confidence Interval
38%
Hazard Ratio
29%
Graft-versus-host Disease (GvHD)
28%
Adult Patients
26%
Older Adults
23%
Non-relapse Mortality
22%
CD34+
20%
Leukemia Patients
19%
High Risk
19%
Minimal Residual Disease
18%
Chimeric Antigen Receptor T-cell Therapy
18%
Cord Blood Transplantation
16%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
16%
Multivariate Analysis
16%
Risk Factors
15%
Umbilical Cord Blood Transplantation
14%
Pretransplant
14%
Marrow Transplantation
14%
Prognostic Significance
13%
Hematopoietic Cell Transplantation-specific Comorbidity Index
13%
Myelodysplastic Syndrome
13%
Allo-RIC
12%
Chemotherapy
12%
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
12%
BCP-ALL
12%
Cumulative Incidence
12%
Hematological Malignancies
11%
American Society
11%
Chimeric Antigen Receptor T Cells (CAR-T)
11%
Relapsed or Refractory
10%
T Cell Depletion
10%
Post-transplant Lymphoproliferative Disorder
10%
Low Incidence
10%
Older Patients
10%
Tisagenlecleucel
10%
Cytomegalovirus
10%
Acute Myeloid Leukemia
9%
Disease-free Survival
9%
Clinical Characteristics
9%
Pediatric Inspired
9%
Cytogenetic Damage
9%
Elderly Patients
9%
Cell Selection
9%
Rituximab
9%
Risk Stratification
9%
Prognostic Impact
9%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
56%
Hematopoietic Cell
45%
Reduced Intensity Conditioning
43%
Overall Survival
38%
Cell Transplantation
36%
Allogeneic Stem Cell Transplantation
29%
Allogeneic Hematopoietic Stem Cell Transplantation
26%
Infection
24%
Hazard Ratio
21%
Graft Versus Host Reaction
21%
Diseases
19%
Chimeric Antigen Receptor T-Cell Immunotherapy
18%
Transplantation
18%
Philadelphia 1 Chromosome
17%
Pediatrics
16%
Cumulative Incidence
16%
Comorbidity
14%
Chemotherapy
14%
T Cell
14%
Myelodysplastic Syndrome
13%
Adolescence
13%
Precursor
12%
Cord Blood Stem Cell Transplantation
12%
Non-Relapse Mortality
12%
B Cell
12%
Epstein Barr Virus
12%
Multivariate Analysis
11%
Chimeric Antigen Receptor T-Cell
11%
Acute Graft Versus Host Disease
11%
Rituximab
11%
Posttransplant Lymphoproliferative Disease
10%
Hematologic Malignancy
10%
Cord Blood
10%
Large-Cell Lymphoma
9%
Acute Myeloid Leukemia
9%
Elderly Patient
9%
Engraftment
8%
Rapamycin
8%
Cytomegalovirus
8%
Minimal Residual Disease
7%
Cancer
7%
Infusion
7%
Chimeric Antigen Receptor
6%
Disease Free Survival
6%
Ex Vivo
6%
Disease Exacerbation
6%
Immunosuppressive Treatment
6%
Malignant Neoplasm
5%
Low Drug Dose
5%
Chronic Graft Versus Host Disease
5%
Immunology and Microbiology
Conditioning
48%
Overall Survival
44%
Allogeneic Hematopoietic Stem Cell Transplantation
35%
Hematopoietic Cell
31%
Cell Transplantation
26%
Allogeneic Stem Cell Transplantation
26%
Graft-Versus-Host Disease
25%
T Cell
23%
B Cell
22%
Cord Blood Stem Cell Transplantation
20%
CD34
16%
Chimeric Antigen Receptor T-Cell Therapy
15%
Comorbidity
14%
Umbilical Cord Blood
13%
Chimeric Antigen Receptor T-Cell
13%
Acute Graft Versus Host Disease
13%
Epstein Barr Virus
13%
Engraftment
12%
Rituximab
11%
CD19
10%
T Cell Depletion
10%
Disease Free Survival
10%
Adolescence
9%
Chronic Graft Versus Host Disease
9%
CD34 Selection
9%
Philadelphia 1 Chromosome
8%
Hematopoietic Stem Cell Transplantation
7%
Anti-Thymocyte Globulin
7%
Myeloid
7%
Mycophenolate Mofetil
6%
Immune Reconstitution
6%
CD3 Antigen
6%
Ciclosporin
5%
Cytomegalovirus
5%
Low Drug Dose
5%
Cytokine Release Syndrome
5%
Recurrence Free Survival
5%
Lymphocyte
5%
Methotrexate
5%